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Aims: Angiotensin-converting enzyme (ACE) inhibitors are used in diabetic kidney disease to reduce system-
ic/intra-glomerular pressure. The objective of this study was to investigate whether reducing blood pressure
(BP) could modulate renal glucose transporter expression, and urinary markers of diabetic nephropathy in
diabetic hypertensive rats treated with ramipril or amlodipine.
Main methods: Diabetes was induced in spontaneously-hypertensive rats (~210 g) by streptozotocin (50 mg/kg).
Thirty days later, animals received ramipril 15 μg/kg/day (R, n = 10), or amlodipine 10 mg/kg/day (A, n = 8,) or
water (C, n = 10) by gavage. After 30-day treatment, body weight, glycaemia, urinary albumin and TGF-β1
(enzyme-linked immunosorbent assay) and BP (tail-cuff pressuremethod)were evaluated. Kidneyswere removed
for evaluation of renal cortex glucose transporters (Western blotting) and renal tissue ACE activity (ﬂuorometric
assay).
Key ﬁndings: After treatments, body weight (p = 0.77) and glycaemia (p = 0.22) were similar among the groups.
Systolic BPwas similarly reduced (p b 0.001) in A and R vs. C (172.4 ± 3.2; 186.7 ± 3.7 and 202.2 ± 4.3 mm Hg;
respectively). ACE activity (C: 0.903 ± 0.086; A: 0.654 ± 0.025, and R: 0.389 ± 0.057 mU/mg), albuminuria (C:
264.8 ± 15.4; A: 140.8 ± 13.5 and R: 102.8 ± 6.7 mg/24 h), and renal cortex GLUT1 content (C: 46.81 ± 4.54;
A: 40.30 ± 5.39 and R: 26.89 ± 0.79 AU) decreased only in R (p b 0.001, p b 0.05 and p b 0.001; respectively).
Signiﬁcance:We concluded that the blockade of the renin–angiotensin systemwith ramipril reduced earlymarkers
of diabetic nephropathy, a phenomenon that cannot be speciﬁcally related to decreased BP levels.© 2013 Elsevier Inc. All rights reserved.Introduction
Prevention and treatment of diabetic nephropathy aim at reducing
blood pressure levels using angiotensin-converting enzyme (ACE) inhib-
itors and attaining low HbA1c levels (The Diabetes Control and
Playstation Trial Research Group, 1993; Lewis et al., 1993). These ap-
proaches are based on clinical trials and experimental research showing
that reduction of systemic blood pressure is important. Notably, ACE in-
hibitors additionally act to reduce intraglomerular pressure, in ways not
shared by other anti-hypertensive drugs (Christensen et al., 2001; Singh
et al., 2003; Souza et al., 2008; Zatz et al., 1986).
The process of renal glucose reabsorption takes place in the epithe-
lial cells of the proximal tubule, involving Na+-glucose transporters
(SGLTs) and facilitative diffusion transporters (GLUTs) (Thorens, 1996).- Hospital de Clínicas de Porto
, 90035-003 Porto Alegre, RS,
an).
rights reserved.The bulk of ﬁltered glucose is reabsorbed in the early S1 segment,
where the low-afﬁnity/high-capacity glucose transporters, SGLT2 and
GLUT2 coexpress in the luminal brush border membrane and in the
basolateralmembrane; respectively. Diabetes is characterized by cortical
GLUT2 gene expression increases (Dominguez et al., 1992, 1994; Marks
et al., 2003; Schaan et al., 2005b), which are important for renal glucose
reabsorptionmaintenance under such condition, as high blood and inter-
stitial glucose concentrationsmay reduce the outwardly directed glucose
gradient from tubule to blood (Dominguez et al., 1994). GLUT1 protein is
also present in the outer renal cortex, where it is related to mesangial
cells (Li et al., 2001). Previously we showed that increased expression
of cortical GLUT1 (mesangial cells) and GLUT2 (S1 tubular cells) is in-
volved in the development of diabetic nephropathy (Schaan et al.,
2001; Vestri et al., 2001). Urinary albumin and transforming growth
factor-β1 (TGF-β1) are increased simultaneously with high GLUT1 and
GLUT2 protein in the renal cortex of streptozotocin (STZ)-treated diabet-
ic rats (Schaan et al., 2001), and all these changes are magniﬁed by the
association with arterial hypertension (Schaan et al., 2005a). The
well-known diabetes-induced GLUT2 overexpression and the further
1175A.S. da Silva et al. / Life Sciences 92 (2013) 1174–1179rise that hypertension can promotemay cause (Freitas et al., 2005, 2007;
Schaan et al., 2005b), in addition to hyperglycaemia (Schaan et al.,
2005a), a further elevation in the interstitial renal glucose concentration,
and more glucose is taken up by mesangial cells through GLUT1.
Since high glucose concentration can increase mesangial angiotensin
II generation and oxidative stress (Cristovam et al., 2008; Takao et al.,
2011; Vidotti et al., 2004), and angiotensin II subsequently can deter-
mine GLUT1 overexpression in mesangial cells (Nose et al., 2003), we
investigated the inhibition of the renin–angiotensin system on cortical
renal GLUT1 and GLUT2 expression in vivo, for the ﬁrst time showing
that ramipril could down-regulate these glucose transporters in the
kidney of STZ-treated diabetic hypertensive rats (Souza et al., 2008).
However, urinary albumin and TGF-β1 levels were not reduced by this
strategy, andwe could not discriminatewhether the effects upon glucose
transporters were caused by reducing blood pressure levels or by
blocking the renin–angiotensin system, as we did not compare ramipril
with non-renin angiotensin system inhibitors.
We hypothesized that ACE-inhibition could be beneﬁcial in treating
diabetic nephropathy beyond its expected role in blood pressure reduc-
tion, as it couldmodulate renal glucose transporters,which are involved
in the pathogenesis of this condition. The objective of this study was
to investigate whether reducing blood pressure levels with ramipril
and amlodipine in diabetic hypertensive rats could modulate renal
glucose transporter expression, as well as urinary markers of diabet-
ic nephropathy.
Materials and methods
Samples and experimental conditions
All animal experimentation procedures followed the Guide for
the Care and Use of Laboratory Animals and Colégio Brasileiro de
Experimentação Animal. (Colégio Brasileiro de Experimentação Animal,
1991; NIH, 1996) The study was approved by the Research Ethics
Committee of Instituto de Cardiologia do Rio Grande do Sul, Brazil.
Experiments were performed in 2-month-old male spontaneously-
hypertensive rats (SHR, Animal House of the Coordenação de Produção
e Experimentação Animal, Fundação Estadual de Produção e Pesquisa
em Saúde, Porto Alegre, RS, Brazil), weighing ~210 g, acclimatized for
1 week. Animals were allowed free access to water and standard rodent
chow diet (Nuvilab CR-1, Nuvital, Curitiba, PR, Brazil), 12-hour light/
12-hour dark cycle, 6 a.m./6 p.m. and stable temperature (23 ± 2 °C)
conditions.
Animals were fasted overnight and rendered diabetic (D) by a single
injection of streptozotocin, 50 mg/kg (Sigma Chemical Co., USA) into the
tail vein. STZ was dissolved in citrate buffer, pH 4.5, and injected slowly,
5 min after its dilution. Diabetes was deﬁned as non-fasting glycaemia
>250 mg/dL (test strips, Advantage, Roche, USA) in tail vein blood
48 h after streptozotocin injection. Animals were maintained for
30 days in individual cages with free access to tap water and standard
rat chow. After that period, they were treated, for 30 days, with water
(C; n = 10), amlodipine (15 mg · kg−1 · day−1, A; n = 8) or ramipril
(1 mg · kg−1 · day−1, R; n = 10), administered by gavage at the same
volume. Afterwards, 24-h urine was collected in metabolic cages for
glucose, albumin and TGF-β1 analyses.
Blood pressure (BP) was measured using a tail-cuff system (Model
229, Ampliﬁer with automatic cuff inﬂation, IITC Life Science Inc.) at
the end of treatments. Animals were placed in a restrainer for 15 min,
a cuff was attached to their tail and BP was then recorded. Animals
were subjected to an adaptation period of one week in order to get
used to that measurement procedure, which was repeated on three
non-consecutive days in the same week. Blood pressure measures
obtained from day 4 were considered valid.
Rats were then anaesthetized with sodium pentobarbitone
(25 mg/kg body weight, iv), their kidneys were perfused with
Hanks' buffer to eliminate the intravascular blood content, and removed(60 days of diabetes, 30 days after ramipril, amlodipine or placebo treat-
ment). Renal outer cortex was dissected and the tissue fragments were
weighed and frozen at −70 °C for further analysis (GLUT1 and GLUT2
protein content).
Glucose, albumin and TGF-β1
Glycaemia (test strips) was evaluated 48 h and 60 days after STZ
injection. Urinary glucose was measured using the colorimetric enzy-
matic test (commercial kit, Merck, Germany).
Samples for the measurement of urinary albumin were collected
without preservatives and stored at −70 °C after centrifugation.
Albuminuria was measured by a quantitative direct enzyme-linked
immunosorbent assay (ELISA, Nephrat, Exocell Inc., USA), using an
anti-rat albumin antibody. The quantiﬁcation range for albuminuria
was 0.156–10 mg/dL. Samples were diluted 1:2. Results are reported
as mg/24 h.
Urinary TGF-β1was assayed by solid phase ELISA (R&DSystems, UK).
Urine samples were collected on ice and centrifuged at 10 000 rpm for
30 min at 4 °C. Supernatant was removed and stored at −70 °C. On
the day of the assay, samples (0.5 mL) were acidiﬁed to pH of 2–3 with
100 μL 1 N HCL for 10 min and then re-neutralized to pH 7–8 with
100 μL of 1.2 N NaOH/0.5 M HEPES. Results are reported as pg/24 h.
The mean intra- and interassay coefﬁcients of variation were 2.0 and
13.1%; respectively.
Angiotensin-converting enzyme activity in renal tissue
ACE activity was determined by ﬂuorometric assay (Santos et al.,
1985). One kidney was quickly harvested, rinsed, blotted and homoge-
nized in 0.4 M sodium borate buffer, pH 7.2. Supernatants from homog-
enized tissues (20 μL) were incubated with 490 or 480 μL of assay buffer
containing 5 mM Hip-His-Leu in 0.4 M sodium borate buffer and 0.9 M
NaCl, pH 8.3, for 15 or 30 min at 37 °C. The reaction was stopped by
the addition of 1.2 mL of 0.34 MNaOH. The product, peptide His-Leu re-
lease, was measured ﬂuorometrically at 365-nm excitation and 495-nm
emission, using a ﬂuorescence spectrometer (Shimadzu, RF 1501, Japan).
o-phthaldialdehyde (100 μL, 20 mg/mL) in methanol was added, and
after 10 min the solution was acidiﬁed with 200 μL 3 N HCl and
centrifuged at 3000 rpm for 10 min at room temperature. In order
to correct for the intrinsic ﬂuorescence of the tissues, time zero
blanks were prepared by adding tissue after NaOH. Assay sensitivity
was ≤0.02 nmol · mg tissue−1 · min−1; ﬂuorescence intensity was
linear with the concentration of His-Leu released from 0.02 to
15 nmol · mg tissue−1 · min−1. The results are reported as nmol
His-Leu · min−1 · mg protein−1, measured with Bradford's method
(bovine serum albumin as standard) (Bradford, 1976).
GLUT1 and GLUT2
Renal cortex was analyzed for GLUT1 and GLUT2 protein content.
Tissue samples were mechanically processed and cell membranes
were disrupted by sonication (Unique, Indaiatuba, SP, Brazil) in
10 w/v buffer (10 mM Tris–HCl, 1 mM EDTA, and 250 mM sucrose,
pH 7.4, containing 5 mg/mL aprotinin), and centrifuged at 3000 ×g
for 15 min. The supernatant was centrifuged at 12 000 ×g for
20 min, and the pellet was suspended as a plasma membrane
enriched fraction (PM). Western blot analysis was then performed
as previously described (Freitas et al., 2005; Schaan et al., 2005a).
Brieﬂy, equal amounts of membrane protein (150 μg) were subjected
to SDS-PAGE (10%) and transferred to nitrocellulose membrane. After
blocking with non-fat-milk, membranes were incubated with the
speciﬁc antibody (#07-1401 and #07-1402, Millipore, Billerica,
USA), 1:3000, followed by washing with saline phosphate buffer
(PBS)/0.05% Tween 20 and incubation with an HRP-conjugated
secondary antibody (AP307P, Millipore, Billerica, USA), 1:10 000.
Fig. 1. Systolic blood pressure (SBP) (panel A) and renal angiotensin-converting
enzyme (ACE) activity (panel B) in the groups studied. *p b 0.05 vs. C; #p b 0.05 vs.
A. Data are reported as means ± SEM. One way ANOVA; post hoc Tukey.
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idase substrate (ECL kit, GE Healthcare, New York, USA) for 1–3 min
and exposed to ultrasensitive radiographic ﬁlm (Kodak, Frankfurt,
Germany) for 1 h. Blot intensity was quantiﬁed by optic densitometry
using Scion Image software. After that, membranes were reprobed
with anti-β-actin antibody (Monoclonal anti-β-actin antibody
AC-74, A2228, Sigma-Aldrich), and GLUT1 and GLUT2 values were
normalized by the respective β-actin value. Results were expressed
as arbitrary units (AU/μg protein).
Histology
In the eleven animals as described above, 3 untreated (C), 4 ramipril-
treated (R) and 4 amlodipine-treated (A) rats, kidney histological analy-
sis was performed searching for ﬁbrosis. After the treatments, rats were
anaesthetized and killed by exsanguination, the right kidney was
removed and ﬁxed in 10% formalin, dehydrated and included in
parafﬁn. Five μm tissue sections were stained with sirius red. The
Image-Pro Plus 6.0.0.206 software was used to capture images and
quantify the corticomedullary junction collagen areas stained in
red. This was performed using a light microscope (BX41, Olympus,
Tokyo, Japan) in original magniﬁcation. Results are presented as
the ratio of ﬁbrotic area to the rest of the kidney photomicrograph.
Data analysis
Data are reported asmeans ± SEMormedian and 25–75 percentiles.
Statistical signiﬁcance was calculated by one-way ANOVA, post hoc
Tukey. Urinary albumin and TGF-β1 data were log-transformed before
analysis. p b 0.05 was considered signiﬁcant, with the critical value of p
being one-sided. The Statistical Package for Social Sciences (version
15.0, SPSS, Chicago, Illinois) was used for data analysis.
Results
Table 1 shows the baseline characteristics of the animals studied
and the metabolic effects of streptozotocin, amlodipine and ramipril
during the experiment. During the entire experimental period, body
weights were similar among groups. Neither group of rats gained
weight, as expected, because of their non-treated diabetic condition.
Moreover, increased glycaemia, urinary glucose excretion and diure-
sis were determined by streptozotocin injection, with no signiﬁcant
difference in these variables among groups, except for glycaemia in
group A at the end of the experiment, as compared to group R.
The results for systolic BP and renal tissue ACE activity are reported in
Fig. 1, panels A and B; respectively. Systolic BP was high in all groups
studied, as expected for hypertensive rats, and decreased by ~10%
(p b 0.007) in animals treated with both anti-hypertensive drugs
amlodipine (A) or ramipril (R). No signiﬁcant difference in BP was ob-
served between groups A and R. Both amlodipine and ramipril treatment
decreased renal tissue ACE activity (17% and 63%; respectively), asTable 1
General characteristics of animals.
C (N = 10) A (N = 8) R (N = 10)
Initial weight (g) 209.1 ± 6.4 214.7 ± 2.2 203.2 ± 4.6
30-day weight (g) 198.4 ± 8.3 195.0 ± 13.5 188.0 ± 5.7
60-day weight (g) 194.7 ± 8.1 192.6 ± 14.4 196.4 ± 5.4
Initial glycaemia (mg/dL) 430.1 ± 34.5 407.5 ± 12.2 360.4 ± 17.3
60-day glycaemia (mg/dL) 532.6 ± 26.9 584.1 ± 6.9* 470.6 ± 27.7
60-day glycosuria (mg/24 h) 984.5 ± 21.5 983.8 ± 33.4 984.2 ± 29.3
60-day diuresis (mg/24 h) 93.7 ± 3.0 91.5 ± 6.1 89.8 ± 4.8
Data are reported as means ± SEM. C: diabetic spontaneously-hypertensive rats con-
trol; A: diabetic spontaneously-hypertensive rats treated with amlodipine 15 mg/kg/
day for 30 days; R: diabetic spontaneously-hypertensive rats treated with ramipril
1 mg/kg/day for 30 days; *p b 0.05 vs R (one-way ANOVA and post hoc Tukey).compared to C. Furthermore, compared to group A, the ACE activity in
group R was reduced (p = 0.022).
Both urinary albumin (Fig. 2, panel A) and TGF-β1 (Fig. 2, panel B)
were high in group C 60 days after the STZ injection. Albuminuria de-
creased in rats treated with both anti-hypertensive drugs tested (A and
R vs. C, p b 0.001), with the lowest levels being observed in R (R vs. A
rats, p = 0.025). Urinary TGF-β1 was increased in group A as compared
to C (p = 0.003). Importantly, TGF-β1 decreased in rats of group R as
compared to C rats (p = 0.028).
Fig. 3 shows that only ramipril caused a signiﬁcant reduction in
renal cortex GLUT1 content (C: 46.81 ± 4.54; A: 40.30 ± 5.39 and R:
26.89 ± 0.79 AU, p = 0.001, panel A). Cortical renal GLUT2 content
was also lower only in R rats (C: 0.68 ± 0.04, A: 0.79 ± 0.06 and R:
0.48 ± 0.03 AU, p = 0.015, panel B).
Fig. 4 depicts representative photomicrographs of picro-sirius red
stained corticomedullary sections (panel A, group C; panel B, group A
and panel C, group R) and the mean and SEM of the ratio of the ﬁbrotic
area of the rest of the kidney protomicrographs analyzed in 3–4 animals
in each group (panel D). No signiﬁcant difference in the ﬁbrotic areawas
observed among the groups studied.
Discussion
The present study demonstrates that, despite similar BP reduction
and no intervention to normalise glycaemia, the ramipril treatment
(blocking the renin–angiotensin system) is, by far, more effective
than the amlodipine treatment in reducing albumin, TGFβ1 urinary
excretion as well as renal glucose transporters in an animal model
of diabetic nephropathy.
Consistent with previous reports by our group and other authors
(Balbinott et al., 2005; Davis et al., 2004; Schaan et al., 2005a), hyper-
tension and hyperglycaemia were present in streptozotocin-treated
SHRs. Consequently, this allowed us to study both the haemodynamic
Fig. 2. Urinary albumin (panel A) and urinary TGFβ1 (panel B) in the groups studied.
*p b 0.05 vs. C, #p b 0.05 vs. A. Data are reported as medians and p25th–75th. One
way ANOVA; post hoc Tukey (data were log-transformed before analysis).
Fig. 3. Renal cortical GLUT 1 (panel A) and GLUT 2 (panel B) protein determined by
Western blot analysis of samples in the groups studied. Loading controls are β-actin.
*p b 0.05 vs. C; #p b 0.05 vs. A. Data are reported as means ± SEM. One way ANOVA;
post hoc Tukey.
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in this animal model. Hyperglycaemia and high levels of urinary glucose
excretion remained stable throughout the study period (60 days), which
was exactly our objective, to maintain hyperglycaemia constant and to
change only BP levels during the experiment. Glycemias were higher in
amlodipine-treated rats as compared to those treated with ramipril,
but glycosurias, which provide a better global estimation of the hyper-
glycemic state throughout the day, were very similar among groups.
Moreover, our objective of reducing BP to similar levels employing
anti-hypertensive agents with different action mechanisms was
achieved. An unexpected ﬁnding, however, was that amlodipine
could reduce the renal angiotensin-converting enzyme activity,
although not at the same magnitude observed in ramipril-treated
rats. Although other authors have reported ACE expression inhibi-
tion by calcium channel blockade in aortic and cardiac tissues of
rats with L-NAME hypertension (Kataoka et al., 2004; Toba et al.,
2005), we report it in the kidney for the ﬁrst time.
High levels of albuminuria, a functional feature of diabetic ne-
phropathy, were effectively reduced by BP reduction with either
agent used, but at a greater magnitude with ramipril. The effect
caused by ramipril was not observed in a previous study (Souza et
al., 2008), probably due to the shorter duration of treatment. In
the present study, however, by using a longer period of treatment,
ramipril-induced reduction in albuminuria was observed, as reported
by other authors in long-term anti-hypertensive treatment in humans
and rats (Parving et al., 1987; Zatz et al., 1986). In addition to the well-
known effect of reduced BP on albuminuria reduction, anti-oxidative
effects induced by renal ACE activity reduction could have contributed
to these effects (Takao et al., 2011; Toba et al., 2005), as diabetic compli-
cations are primarily determined by excessive generation of reactive
oxygen species (Brownlee, 2005).
Importantly, the high levels of urinary TGF-β1, amolecular marker of
diabetic renal injury (Bertoluci et al., 1996), were evenmore elevated by
the use of amlodipine, irrespective of reduced BP, whereas they were
effectively reduced by ramipril. This particular effect of ramipril waspreviously shown in humans with diabetic nephropathy and non-
diabetic renal proteinuric diseases (Bertoluci et al., 2006; Praga et
al., 2003). The effect of amlodipine on increasing urinary TGF-β1
levels has also been reported previously (Praga et al., 2003). Further-
more, in the same animal model we used, Chen et al. (2002) reported
that the renal protein expression of TGF-β1 measured by Western
analysis can be prevented by ACE blocker cilazapril, but not by
amlodipine, reinforcing local angiotensin II system involvement in
the pathogenesis of renal injury in hypertensive diabetic rats by
stimulating TGF-β1 expression. The powerful effect of ramipril on
reducing renal angiotensin-converting enzyme activity, as compared
to that of amlodipine, could account for the different effects of these
drugs.
High levels of TGF-β1 presented by amlodipine-treated rats could
cause overexpression of PAI-1, decreasing degradation and/or increasing
production of extracellular matrix, leading to renal ﬁbrosis. However,
despite opposite changes observed in TGF-β1 of amlodipine- and
ramipril-treated rats,ﬁbrosiswas not different between groups, showing
that early changes in TGF-β1 were not yet accompanied by structural
changes (ﬁbrosis). Previous studies showed that Ang-II type 1 receptor
(AT-1R) blockers could suppress the expression of TGF-β1 in the kidney
of diabetic rats and attenuate renal lesions (Arozal et al., 2009;
Lakshmanan et al., 2012). The different ways of blocking the renin–an-
giotensin system could account for the different results obtained in the
present study. Moreover, no previous study showed the possible delete-
rious effect of amlodipine upon the functionalmarker of ﬁbrosis, TGF-β1.
Fig. 4. Representative photomicrographs of Sirius red staining of C (panel A), A (panel
B) and R (panel C) groups; collagens were stained as red. Data are reported as
means ± SEM (Panel D). One way ANOVA; post hoc Tukey.
1178 A.S. da Silva et al. / Life Sciences 92 (2013) 1174–1179Mechanical stretch imposed by systemic hypertension on glomeru-
lar structures can itself promote overexpression of GLUT1, amechanism
that involves TGF-β1 signaling activation, suggesting that lowering BP
levels, as observed previously (Souza et al., 2008), could be involved
in GLUT1 expression reduction. In that report (Souza et al., 2008), we
could not differentiate the effects of reducing BP and inhibiting the
ACE with ramipril, as we are now showing with the present study
design.Now we are reporting a reduction of GLUT1 and GLUT2 content in
rats treated with ramipril, which is expected to reduce the mesangial
cell glucose disposal, contributing to reduction in the extracellular
matrix production. Importantly, this effect on glucose transporter ex-
pression modulation does not seem to be only a consequence of BP
lowering, but also related to mechanisms involving glucose transport.
GLUT1 is the predominant glucose transporter in mesangial cells (Li
et al., 2001), and GLUT1 overexpression in cultured mesangial cells
induces increased glucose uptake and synthesis of extracellular matrix,
collagen IV and ﬁbronectin (Heilig et al., 1995). Additionally, changes
in cortical renal GLUT1 expression have been associated with the
development of diabetic nephropathy in vivo (Schaan et al., 2001,
2005a), and studies in transgenic mice and clinical investigations of the
XbaI polymorphic alleles in intron 2 of the human SLC2A1 gene, which
codiﬁes the GLUT1 protein, have also associated changes in GLUT1
with nephropathy (Heilig et al., 2006). Non-diabetic transgenic mice,
overexpressing glomerular GLUT1 protein predominantly in mesangial
cells, develop microalbuminuria and glomerulosclerosis similar to that
observed in diabetic mice (Wang et al., 2010). Finally, diabetic patients
with the TT genotype at A–2841T in SLC2A1 gene (Hodgkinson et al.,
2005), and diabetic or non-diabetic subjects with the SLC2A1 Enh2SNP1
homozygous AA genotype are at increased risk for kidney disease (Hsu et
al., 2011). For these processes related to GLUT1 overexpression in
mesangial cells, increased GLUT2 expression in tubular cells plays a
fundamental role, contributing to increased interstitial glucose concen-
tration. Whether the effect of ramipril on glucose transporters is able to
nullify established damage or not will depend on the reversibility of
these derangements, but it probably would decelerate the progression
of nephropathy.
The present study was not designed to demonstrate molecular
mechanisms involved in the observed effects of ramipril; however, we
might speculate that the changes in glucose transporters not only
could be a consequence of decreased levels of Ang-II, but also involve
other ACE inhibition-induced effects such as increased bradykinin
(Dendorfer et al., 2000; Soehnlein et al., 2005), potentiation of other
kinins (Dendorfer et al., 2001), and high nitric oxide availability (Otto
et al., 2006). Further studies should be designed to demonstrate the
ACE inhibition-mediated mechanisms related to renal glucose trans-
porter regulation.
Conclusions
The ramipril treatment (blocking the renin–angiotensin system) is,
by far, more effective than the amlodipine treatment in reducing
albumin, TGFβ1 urinary excretion as well as renal glucose transporters
in an animal model of diabetic nephropathy. These results highlight
that ACE inhibitor ramipril presents beneﬁts not only associated with
BP reduction in diabetic hypertensive individuals. Further studies should
be performed to ﬁnd out whether the beneﬁcial effects of lowering BP
with ramipril or other ACE inhibitors on renal glucose transporters
expression are sustained for longer periods of time, and whether
reducing glycaemia would have additive effects on the present ﬁndings.
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